Help improve the information
Suggest a correction, missing detail, or peptide addition by .
Not FDA approved
This peptide is not FDA approved for human use, and because peptides are often incompletely studied you should not use or self-experiment with it outside qualified medical supervision.
Overview
Adalank is marketed as N-Acetyl Selank Amidate, a modified Selank derivative built on the heptapeptide sequence TKPRPGP. The reviewed source set did not identify indexed PubMed papers that directly study Adalank or N-Acetyl Selank Amidate by name.
Most claims around the compound therefore come from parent-compound Selank research plus general peptide-chemistry assumptions about terminal acetylation and amidation, rather than direct published evidence for the exact derivative.
Reported benefits
- Clear relationship to Selank and tuftsin-analogue chemistry.
- Parent-compound Selank has published human anxiety literature.
- Terminal modification is intended to alter stability, but direct published Adalank evidence was not identified.
- Best framed as a research or gray-market derivative, not an established therapy.
Mechanism of action
The current source set does not support a directly proven mechanism for exact Adalank. Claims about GABAergic effects, monoamine balance, BDNF (a protein involved in brain cell growth and maintenance) signaling, longer half-life (how long it stays active), or improved blood-brain barrier (the protective filter around the brain) penetration are mostly carried over from parent Selank discussions and general chemistry logic about acetylation and amidation.
That is hypothesis-level reasoning, not direct published confirmation for the exact modified compound.
Reported Use
No FDA dosing guidance
This peptide is not covered by FDA-labeled dosing guidance on this page. Peptides are often investigational or incompletely studied. Do not self-experiment; use only with a doctor or qualified clinician.
Typical dose
No source-backed human dosing protocol was identified for exact Adalank
Frequency
Not established
Injection sites
Gray-market injection use should not be treated as evidence-based just because Selank has a different intranasal product context
Best timing
Not established
Effects timeline
Not established
Storage
Do not treat generic peptide-vial instructions as validated Adalank protocol
Cycle length
Not established
Break between
Not established
Sequence
TKPRPGP
Loading viewer
Preparing 3D peptide scene
Quick Signals
At A Glance
A faster read on evidence, focus, structure, and status.
Evidence
Limited published research
No direct indexed Adalank literature was identified in the reviewed source set.
No indexed studiesCurrent level
Low evidence
Scale: low evidence to established use
Status
Regulatory and sport context
Safety
Side Effects And Safety
Switch between common side-effect notes and stop criteria to keep safety context visible.
Reported or plausible side effects
- Neuropsychiatric use still warrants caution around mood change, sedation, paradoxical effects, and co-use with psychiatric medications.
- Local irritation, sterility risk, and formulation quality are major concerns in gray-market products.
Key cautions
- No direct human safety program for exact Adalank was identified.
- Parent Selank tolerability data should not be treated as full safety proof for the modified compound.
- Marketing claims about no tolerance, no withdrawal, or no dependency are too absolute for the exact derivative.
Molecule
Molecular Information
Core structure fields that help explain what kind of peptide this is and how much sequence detail is available.
Molecular weight
792.93 Da (sequence-derived estimate for the curated amidated structure)
Chain length
7 amino acids
Sequence type
Modified heptapeptide
Derived from
Modified Selank / tuftsin-analogue chemistry
Amino acid sequence source string
Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2
N-terminal acetylation and C-terminal amidation
Context
Important Context
The main context that changes how confidently this peptide should be interpreted.
Research status
No direct indexed Adalank literature was identified in the reviewed source set. Stronger human evidence exists for parent-compound Selank, and most marketed Adalank claims are extrapolated from that literature plus chemistry assumptions about terminal modification.
Regulatory and sport status
FDA review shows it is not FDA approved. based on reviewed openFDA query. Sport review: likely S0 prohibited; athlete-specific review advised.
Route Notes
Route-Specific Notes
Only shown when the source material adds route-specific details beyond the quick-start guide.
Injectable
- Administration: No source-backed injected Adalank administration protocol was identified.
- Absorption: No direct pharmacokinetic data for exact injected Adalank was identified.
- Cycle: Not established
- Additional: Gray-market injectable use should not be treated as validated clinical guidance.
Intranasal
- Administration: Parent-compound Selank intranasal context does not validate generic Adalank intranasal use.
- Absorption: Claims about improved absorption or brain penetration are theoretical and not directly established for exact Adalank.
- Cycle: Not established
- Additional: No source-backed non-injectable Adalank dosing protocol was identified.
Compare
How Well Documented Is It?
A quick five-point snapshot of how visible and well-documented this peptide is. Higher values mean more coverage or clearer status in that area, not better medical performance.
Research
How much published research coverage this peptide has in the linked sources, with an approval-context floor for clearly established drug products.
Source: PubMed
Regulatory
How clearly the approval or regulatory status is documented for this entry.
Source: openFDA drugsfda API
Sport
How clearly sports or competition status is documented in the linked review sources.
Source: WADA Prohibited List
Breadth
How broadly this peptide appears across discussion topics and use-case groupings in the catalog.
Source: Curated site taxonomy
Sequence
How much structure or residue-sequence detail is available for this entry.
Source: Sequence
Protocols
Research Protocols
Common protocol-style rows shown in a consistent table layout so every peptide page is easy to compare.
| Goal | Dose | Route | Frequency |
|---|---|---|---|
| Exact Adalank literature | No direct indexed human or preclinical protocol identified | Not established | Not established |
| Parent Selank extrapolation context | Study-specific for Selank, not transferable by default to Adalank | Usually intranasal in the better-supported parent-compound literature | Study-specific |
Research
What It Has Been Studied For
Plain-language summaries of the main health areas where this peptide shows up in the linked research.
Stacking
What People Commonly Stack It With
A plain-language view of compounds that are commonly discussed alongside this peptide in the source material.
Practical
Preparation, Quality, And Expectations
Operational checklist blocks designed for quick scanning and repeatable page structure.
How to reconstitute
- •No validated consumer reconstitution protocol was identified for exact Adalank.
- •Do not treat generic BAC-water instructions as source-backed medical guidance.
- •Identity, concentration, and sterility should be considered unresolved unless independently documented.
Quality indicators
Good signs
- Product identity clearly states the exact modified compound.
- Traceable manufacturing and handling records are available.
- Claims clearly distinguish parent Selank data from exact Adalank data.
Avoid
- Confident claims about direct Adalank clinical evidence when the cited study is actually on Selank.
- Generic injection or intranasal dosing presented as established.
- Vague product identity or unclear formulation.
- Marketing that implies sports permissibility.
What to expect
No reliable human expectation timeline was established for exact Adalank.
Any predicted timing is mostly extrapolated from parent Selank or from general peptide-modification assumptions.
References
Research And Source List
Structured reference cards with source metadata and a direct link so users can inspect the original study/source.
PubMed exact-name Adalank query
PubMed search
Exact-name query used to check for indexed Adalank literature; no direct results were identified in the reviewed source set.
PubChem N-Acetyl selank record
PubChem CID 133082488
Closest registry record identified in the reviewed source set, but not the exact amidated Adalank form.
Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia
Parent Selank human anxiety trial
Parent-compound Selank randomized trial frequently used to support Adalank marketing claims, but it does not directly study Adalank.
Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment
Parent Selank cognition and BDNF context
Parent-compound paper often cited for cognitive and BDNF-related claims that are later extended to Adalank without direct verification.
Selank Administration Affects the Expression of Genes Involved in the GABAergic Neurotransmission System in IMR-32 Neuroblastoma Cells
Parent Selank mechanistic paper
Parent-compound mechanistic study relevant to common neuroactive claims, but not direct proof for Adalank.
Vidal Selank page
Drug reference
Current non-US parent-compound product context used to separate Selank from exact Adalank claims.
openFDA Adalank query
FDA database query
Approval-database query used for status review; no FDA-approved Adalank product was identified in the reviewed source set.
WADA Prohibited List
Official anti-doping reference
Official WADA prohibited-categories reference used for current sport-status review.
WADA S0 page
Non-approved substances
Official WADA page for non-approved substances, relevant to the current Adalank sports-status framing.